{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:31:01Z","timestamp":1789986661988,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,8,28]],"date-time":"2013-08-28T00:00:00Z","timestamp":1377648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1038\/ja.2013.84","type":"journal-article","created":{"date-parts":[[2013,8,28]],"date-time":"2013-08-28T06:15:49Z","timestamp":1377670549000},"page":"705-708","source":"Crossref","is-referenced-by-count":35,"title":["In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii"],"prefix":"10.1038","volume":"66","author":[{"given":"Wentao","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,28]]},"reference":[{"key":"BFja201384_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/cc5911","volume":"11","author":"ME Falagas","year":"2007","unstructured":"Falagas, M. E. & Rafailidis, P. I. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit. Care 11, 134 (2007).","journal-title":"Crit. Care"},{"key":"BFja201384_CR2","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1128\/AAC.01464-06","volume":"51","author":"F Perez","year":"2007","unstructured":"Perez, F. et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 3471\u20133484 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201384_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2174\/157489108784746560","volume":"3","author":"V Bos\u00f3-Ribelles","year":"2008","unstructured":"Bos\u00f3-Ribelles, V., Rom\u00e1-S\u00e1nchez, E., Carmena, J., C\u00e1ceres, C. & Bautista, D. Tigecycline: a new treatment choice against Acinetobacter baumannii. Recent Pat. Antiinfect. Drug Discov. 3, 117\u2013122 (2008).","journal-title":"Recent Pat. Antiinfect. Drug Discov."},{"key":"BFja201384_CR4","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1517\/14656566.2011.599320","volume":"12","author":"SS Jean","year":"2011","unstructured":"Jean, S. S. & Hsueh, P. R. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin. Pharmacother. 12, 2145\u20132148 (2011).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFja201384_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1345\/aph.1P187","volume":"45","author":"TW Cooper","year":"2011","unstructured":"Cooper, T. W., Pass, S. E., Brouse, S. D. & Hall Ii, R. G. Can pharmacokinetic and pharmacodynamic principles be applied to the treatment of multidrug-resistant acinetobacter? Ann. Pharmacother. 45, 229\u2013240 (2011).","journal-title":"Ann. Pharmacother."},{"key":"BFja201384_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijantimicag.2012.09.005","volume":"41","author":"Y Sun","year":"2013","unstructured":"Sun, Y. et al. The emergence of clinical resistance to tigecycline. Int. J. Antimicrob. Agents 41, 110\u2013116 (2013).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFja201384_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1086\/526775","volume":"46","author":"KB Anthony","year":"2008","unstructured":"Anthony, K. B. et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46, 567\u2013570 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201384_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1128\/AAC.00766-07","volume":"52","author":"JS Hawley","year":"2008","unstructured":"Hawley, J. S., Murray, C. K. & Jorgensen, J. H. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 52, 351\u2013352 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201384_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/jac\/dkm305","volume":"60","author":"KS Ko","year":"2007","unstructured":"Ko, K. S. et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 60, 1163\u20131167 (2007).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja201384_CR10","doi-asserted-by":"publisher","first-page":"8.e1-8.e9","DOI":"10.1016\/j.ijantimicag.2008.11.006","volume":"34","author":"JM Entenza","year":"2009","unstructured":"Entenza, J. M. & Moreillon, P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 34, 8.e1-8.e9 (2009).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFja201384_CR11","first-page":"S21","volume":"M100","author":"National Committee for Clinical Laboratory Standards (NCCLS)","year":"2011","unstructured":"National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing. Information Supplement. M100, S21 (2011).","journal-title":"Information Supplement."},{"key":"BFja201384_CR12","first-page":"365","volume-title":"Antibiotics in Laboratory Medicine","author":"SK Pillai","year":"2005","unstructured":"Pillai, S. K., Moellering, R. C. & Eliopoulos, G. M. Antimicrobial Combinations in Antibiotics in Laboratory Medicine 5th edn ed Lorian V. L., 365\u2013424 Lippincott Williams & Wilkins: Philadelphia, (2005)."},{"key":"BFja201384_CR13","first-page":"1","volume-title":"Clinical Microbiology Procedures Handbook","author":"J Moody","year":"2004","unstructured":"Moody, J. Synergism testing: broth microdilution checkerboard and broth macrodilution method in Clinical Microbiology Procedures Handbook ed Isenberg H. D.), 2nd edn 1\u201328 ASM: Washington, DC, (2004)."},{"key":"BFja201384_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/jac\/dkg269","volume":"52","author":"K Drlica","year":"2003","unstructured":"Drlica, K. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52, 11\u201317 (2003).","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl 3","key":"BFja201384_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1086\/321841","volume":"33","author":"X Zhao","year":"2001","unstructured":"Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33 (Suppl 3), 147\u2013156 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"BFja201384_CR16","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1128\/AAC.01620-05","volume":"50","author":"GG Zhanel","year":"2006","unstructured":"Zhanel, G. G., Mayer, M., Laing, N. & Adam, H. J. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50, 2228\u20132230 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201384_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1586\/14787210.6.3.309","volume":"6","author":"TD Gootz","year":"2008","unstructured":"Gootz, T. D. & Marra, A. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev. Anti Infect. Ther. 6, 309\u2013325 (2008).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"BFja201384_CR18","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1164\/rccm.201102-0349OC","volume":"184","author":"DR Chung","year":"2011","unstructured":"Chung, D. R. et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am. J. Respir. Crit. Care Med. 184, 1409\u20131417 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFja201384_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1099\/jmm.0.036939-0","volume":"61","author":"KR Peck","year":"2012","unstructured":"Peck, K. R. et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. J. Med. Microbiol. 61, 353\u2013360 (2012).","journal-title":"J. Med. Microbiol."},{"key":"BFja201384_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/ja.2009.117","volume":"63","author":"M Dizbay","year":"2010","unstructured":"Dizbay, M. et al. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J. Antibiot. (Tokyo) 63, 51\u201353 (2010).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja201384_CR21","first-page":"8","volume":"21","author":"L Principe","year":"2009","unstructured":"Principe, L., D'Arezzo, S., Capone, A., Petrosillo, N. & Visca, P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann. Clin. Microbiol. Antimicrob. 21, 8\u201318 (2009).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"BFja201384_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1179\/1973947812Y.0000000029","volume":"24","author":"A Deveci","year":"2012","unstructured":"Deveci, A. et al. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates. J. Chemother. 24, 247\u2013252 (2012).","journal-title":"J. Chemother."},{"key":"BFja201384_CR23","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1128\/AAC.00264-10","volume":"54","author":"Y Cai","year":"2010","unstructured":"Cai, Y. et al. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob. Agents Chemother. 54, 3998\u20133999 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja201384_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ja.2009.111","volume":"63","author":"JC Cui","year":"2010","unstructured":"Cui, J. C., Liu, Y. N. & Chen, L. A. Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii. J. Antibiot. (Tokyo) 63, 29\u201331 (2010).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja201384_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ijantimicag.2012.06.018","volume":"40","author":"Y Cai","year":"2012","unstructured":"Cai, Y. et al. Mutant prevention concentration of colistin alone and in combination with levofloxacin or tobramycin against multidrug-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 40, 477\u2013478 (2012).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFja201384_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1179\/joc.2010.22.3.175","volume":"22","author":"GL Daikos","year":"2010","unstructured":"Daikos, G. L. et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J. Chemother. 22, 175\u2013178 (2010).","journal-title":"J. Chemother."},{"key":"BFja201384_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1128\/AAC.32.1.42","volume":"32","author":"DP Reitberg","year":"1988","unstructured":"Reitberg, D. P. et al. Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination. Antimicrob. Agents Chemother. 32, 42\u201346 (1988).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ja201384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja201384","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja201384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:20:05Z","timestamp":1684430405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja201384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,28]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["BFja201384"],"URL":"https:\/\/doi.org\/10.1038\/ja.2013.84","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,28]]}}}